Retatrutide, a triple incretin agonist, achieves remarkable 24.2% weight loss, 2.02% HbA1c reduction, and up to 82% liver fat normalization in phase 2 trials. It also reduces cardiovascular risk by 26.9% through lipid improvements and supports kidney function. Clinical research has explored the potential of multi-receptor peptides like Retatrutide as part of the evolving landscape of weight management and metabolic health. As a next-generation GLP-1/GIP receptor agonist, studies suggest it may offer advantages beyond traditional peptides such as semaglutide (Ozempic) in areas like fat reduction, appetite regulation, and metabolic support.